Precision Optics Corporation, Inc. reports recurring business developments in advanced optical instruments for the medical and defense/aerospace industries. The company designs, develops and manufactures custom optical medical devices, endoscopes, endocouplers and related optical assemblies, with news frequently covering single-use endoscopy programs and customer production orders.
Updates for POCI also include product-development work for aerospace and defense applications, including small-diameter borescope systems used in jet-engine inspection. Company announcements commonly address fiscal-period operating results, conference calls, customer program activity, backlog and pipeline commentary, and capital-structure actions involving its Nasdaq-listed common stock.
Precision Optics (POCI) will present by webcast at the virtual Lytham Partners Fall 2026 Investor Conference on September 29, 2026. The webcast is scheduled for 3:15 p.m. ET, with a replay available afterward. Management will hold virtual one-on-one investor meetings during the September 29–30 event.
Precision Optics (POCI) reported fiscal 2026 revenue of $31.5 million, up approximately 65% from fiscal 2025.
Fourth-quarter revenue was $8.8 million, versus $6.2 million a year earlier, as gross margin rose to 25.3% from 13.0%. The quarterly net loss narrowed to $0.1 million from $1.4 million. The full-year net loss narrowed to $3.6 million from $5.8 million, but annual gross margin slipped to 17.2% from 17.8%. Cash was $9.8 million at June 30, 2026, versus $1.8 million a year earlier.
Precision Optics expects fiscal 2027 revenue of $30 million to $33 million and adjusted EBITDA, a non-GAAP earnings measure, of negative $1.2 million to negative $1.7 million. The outlook reflects paused demand from an existing satellite customer; orders are expected to resume in the second half. A public offering issued 3,194,444 shares in fiscal 2026, and the company received a $1.3 million defense follow-on order.
Precision Optics (POCI) scheduled a conference call for September 28, 2026, to discuss its fourth-quarter and full-year fiscal 2026 results.
The call is set for 5:00 p.m. ET. The company intends to release the results and file its 10-K after the market closes that day, before the call. Telephone and webcast replays will be available; the telephone replay will remain accessible through October 5, 2026.
Precision Optics (POCI) received an initial $50,000 development order from a U.S. space technology company on September 17, 2026, to support early engineering work on laser communication subassemblies for Optical Communication Terminals in a new satellite constellation.
This order establishes the company’s second satellite customer and will support an accelerated development schedule. The early engineering phase is expected to be completed in about one month, with the customer’s goal to begin production within approximately six to twelve months. Precision Optics expects this initial work to lead to a comprehensive engineering agreement for final designs and a later transition to production, potentially moving further up the value chain within OCT systems.
Precision Optics (POCI) received approximately $1.3 million in follow-on production orders from a large U.S. defense contractor for complex optical assemblies first manufactured in 2018.
The company believes the underlying defense program could remain in production for at least the next ten years. Precision Optics and its customer expect to negotiate a long-term manufacturing agreement in the coming months, with a structured order framework aimed at reducing order gaps and supporting more continuous manufacturing. The company said this structure is expected to preserve manufacturing continuity and knowledge, improve planning and throughput, and generate cost efficiencies while providing a strong base of recurring business for its micro-optics group.
Precision Optics (Nasdaq: POCI) announced the appointment of Peter Thier as Senior Vice President of Sales and Marketing, effective August 18, 2026. According to Precision Optics, Thier will lead the company’s sales and marketing strategy across its medical, defense and aerospace markets.
Thier brings more than 30 years of experience in sales, business development, strategy and commercial leadership in medical technology, life sciences and advanced product development. In connection with his hiring, the board approved an inducement stock option for 50,000 shares of common stock, granted under Nasdaq Rule 5635(c)(4). The option has a 10‑year term, an exercise price equal to the Nasdaq closing price on August 18, 2026, and vests in three equal annual installments over three years, subject to continued service.
Precision Optics (Nasdaq: POCI) will participate in a webcast presentation at the Lytham Partners 2026 Consumer & Technology Investor Summit, held virtually on Tuesday, August 18, 2026. The company’s presentation is scheduled for 2:30 p.m. ET that day.
The webcast can be accessed via the summit home page at https://lythampartners.com/cts2026/ or directly at https://lythampartners.com/cts2026/poci, with a replay available through the same links. Founded in 1982, Precision Optics designs and manufactures advanced micro-optics, 3D imaging and digital imaging products for healthcare and defense/aerospace markets.
Precision Optics (Nasdaq:POCI) will present at the Planet MicroCap Las Vegas 2026 Investor Conference on Wednesday, June 17, 2026, at 11:00 a.m. Pacific time at the Bellagio Resort & Hotel in Las Vegas.
The presentation will be available via live webcast, and management will also hold in-person 1x1 investor meetings on June 17-18 for registered conference attendees.
Precision Optics (Nasdaq: POCI) will participate in the virtual Lytham Partners Spring 2026 Investor Conference on May 28, 2026. The Company will host a webcast presentation and conduct one-on-one investor meetings.
The webcast is scheduled for 1:00 p.m. ET and will be available for replay after the event.
Precision Optics (NASDAQ:POCI) reported record Q3 FY2026 revenue of $8.7 million, up about 108% year-over-year, with production revenue at $7.6 million and engineering revenue at $1.1 million. Gross margin rose to 23.6%, net loss narrowed to $0.1 million, and adjusted EBITDA was $0.3 million.
The company raised FY2026 revenue guidance to $29–$31 million and tightened adjusted EBITDA guidance to a loss of $2.5–$2.7 million. It completed an oversubscribed $10 million public offering and received a $3.5 million follow-on ophthalmic order.